- C4 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
- C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- C4 Therapeutics to Participate in the Stifel 2024 Targeted Oncology Forum
- C4 Therapeutics Presents New Preclinical Data for CFT1946 Highlighting Superior Activity as a Single Agent to Clinically Approved BRAF Inhibitor Standard of Care Combinations at the American Association for Cancer Research Annual Meeting 2024
- C4 Therapeutics to Present New Preclinical Data on Highly Selective Orally Bioavailable BiDAC™ Degraders at the American Association for Cancer Research Annual Meeting 2024
- C4 Therapeutics Announces Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Germany, Against Critical Oncogenic Proteins
- C4 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
- C4 Therapeutics Announces 2024 Priorities and Extended Cash Runway to Advance Portfolio of Targeted Protein Degradation Medicines
- C4 Therapeutics Announces Closing of $25 Million Equity Investment by Betta Pharmaceuticals
- C4 Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
More ▼
Key statistics
On Friday, C4 Therapeutics Inc (CCCC:NSQ) closed at 4.66, 339.62% above the 52 week low of 1.06 set on Dec 06, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 4.72 |
---|---|
High | 4.94 |
Low | 4.61 |
Bid | 4.68 |
Offer | 4.98 |
Previous close | 4.66 |
Average volume | 1.20m |
---|---|
Shares outstanding | 68.81m |
Free float | 60.73m |
P/E (TTM) | -- |
Market cap | 340.59m USD |
EPS (TTM) | -2.37 USD |
Data delayed at least 15 minutes, as of Jun 07 2024 21:00 BST.
More ▼